Want to join the conversation?
Cambridge, Massachusetts-based $BIIB said opicinumab, a monoclonal antibody being developed as a potential neuroreparative therapy to treat people with relapsing forms of multiple sclerosis, has missed its primary endpoint. The company added that evidence of a clinical effect with a complex, unexpected dose-response was observed.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.